The stock of Takeda Pharmaceutical Co ADR (NYSE: TAK) has decreased by -0.33% when compared to last closing price of $15.07. Despite this, the company has experienced a -2.85% fall in its stock price over the last five trading sessions. businesswire.com reported 2025-06-30 that OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for people two years of age and older with primary immunodeficiency (PI). As a ready-to-use liquid, GAMMAGARD.
Is It Worth Investing in Takeda Pharmaceutical Co ADR (NYSE: TAK) Right Now?
Takeda Pharmaceutical Co ADR (NYSE: TAK) has a higher price-to-earnings ratio of 69.12x compared to its average ratio, The 36-month beta value for TAK is at 0.27. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for TAK is 3.15B, and currently, shorts hold a 0.21% of that float. The average trading volume for TAK on July 09, 2025 was 2.16M shares.
TAK’s Market Performance
TAK’s stock has seen a -2.85% decrease for the week, with a 0.20% rise in the past month and a 2.04% gain in the past quarter. The volatility ratio for the week is 1.02%, and the volatility levels for the past 30 days are at 1.00% for Takeda Pharmaceutical Co ADR The simple moving average for the last 20 days is -0.63% for TAK stock, with a simple moving average of 5.61% for the last 200 days.
Analysts’ Opinion of TAK
BofA Securities, on the other hand, stated in their research note that they expect to see TAK reach a price target of $20. The rating they have provided for TAK stocks is “Buy” according to the report published on March 16th, 2023.
Cowen gave a rating of “Outperform” to TAK, setting the target price at $24 in the report published on July 19th of the previous year.
TAK Trading at 1.04% from the 50-Day Moving Average
After a stumble in the market that brought TAK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.28% of loss for the given period.
Stock Fundamentals for TAK
Current profitability levels for the company are sitting at:
- 0.1 for the present operating margin
- 0.55 for the gross margin
The net margin for Takeda Pharmaceutical Co ADR stands at 0.02. The total capital return value is set at 0.04. Equity return is now at value 1.50, with 0.73 for asset returns.
Based on Takeda Pharmaceutical Co ADR (TAK), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at 0.21. The debt to equity ratio resting at 0.65. The interest coverage ratio of the stock is 2.1.
Currently, EBITDA for the company is 874.6 billion with net debt to EBITDA at 3.57. When we switch over and look at the enterprise to sales, we see a ratio of 2.42. The receivables turnover for the company is 6.32for trailing twelve months and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.01.
Conclusion
In conclusion, Takeda Pharmaceutical Co ADR (TAK) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
